 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...191192193194195196197198199200201...235236» |
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Journal: Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials. (Pubmed Central) - Apr 22, 2017
P3
These biomarkers have implications for patient management at recurrence. clinicaltrials.gov Identifiers: NCT00079274 and NCT00096278.
- | Phase classification, Metastases: Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer (clinicaltrials.gov) - Apr 21, 2017
P1, N=36, Recruiting, Sponsor: University of Chicago
clinicaltrials.gov Identifiers: NCT00079274 and NCT00096278. Phase classification: P4 --> P1
- Stivarga (regorafenib) / Bayer
Trial primary completion date, Metastases: FOLFOX Plus Regorafenib in Patients With Unresectable or Metastatic Esophagogastric Cancer (clinicaltrials.gov) - Apr 20, 2017
P2, N=36, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Phase classification: P4 --> P1 Trial primary completion date: Jul 2017 --> Jul 2018
- || davamotecan pegadexamer (EP0057) / Ellipses Pharma
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors (clinicaltrials.gov) - Apr 20, 2017
P1, N=61, Active, not recruiting, Sponsor: NewLink Genetics Corporation
Trial primary completion date: Jul 2017 --> Jul 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Oct 2017
- |||| napabucasin (BBI608) / Sumitomo Pharma
Trial primary completion date, Combination therapy, Metastases: CanStem303C trial: A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 20, 2017
P3, N=1250, Recruiting, Sponsor: Boston Biomedical, Inc
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> Oct 2017 Trial primary completion date: Jun 2019 --> Jun 2020
- | oxaliplatin / Generic mfg., capecitabine / Generic mfg.
Biomarker, Journal: Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin. (Pubmed Central) - Apr 20, 2017
Trial primary completion date: Jun 2019 --> Jun 2020 In the present exploratory analysis, CIMP did not appear to be a prognostic biomarker in oxaliplatin-treated patients with resected colorectal cancer.
- | oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New trial, Metastases: Home Parenteral Nutrition for Malnourished Unresectable Stage IV Gastric Cancer (clinicaltrials.gov) - Apr 20, 2017
P=N/A, N=20, Recruiting, Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
- | Avastin (bevacizumab) / Roche
Trial completion, Combination therapy, Metastases: Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 19, 2017
P1, N=17, Completed, Sponsor: National Cancer Institute (NCI)
In the present exploratory analysis, CIMP did not appear to be a prognostic biomarker in oxaliplatin-treated patients with resected colorectal cancer. Active, not recruiting --> Completed
- || AL101 / Ayala Pharma
Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Apr 19, 2017
P1, N=95, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Jun 2017
- || Enrollment change, Monotherapy, Metastases: Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab/Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001) (clinicaltrials.gov) - Apr 18, 2017
P1, N=260, Recruiting, Sponsor: Merck Sharp & Dohme Corp.
Trial primary completion date: Dec 2016 --> Jun 2017 N=70 --> 260
- | Avastin (bevacizumab) / Roche
New P2 trial: CLavSyn: Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels (clinicaltrials.gov) - Apr 17, 2017
P2, N=177, Not yet recruiting, Sponsor: Centre Hospitalier Universitaire de Besancon
- || dilpacimab (ABT-165) / AbbVie
Trial primary completion date, Metastases: A Study of ABT-165 in Subjects With Solid Tumors (clinicaltrials.gov) - Apr 17, 2017
P1, N=90, Recruiting, Sponsor: AbbVie
N=70 --> 260 Trial primary completion date: Apr 2017 --> Jun 2018
- foscenvivint (PRI724) / PRISM Pharma, Ohara Pharma, Avastin (bevacizumab) / Roche
Enrollment change, Trial withdrawal, Metastases: PRIMIER: Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients With Newly Diagnosed Metastatic Colorectal Cancer (clinicaltrials.gov) - Apr 17, 2017
P2, N=0, Withdrawn, Sponsor: University of Southern California
Trial primary completion date: Apr 2017 --> Jun 2018 N=100 --> 0 | Not yet recruiting --> Withdrawn
- | oxaliplatin / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies (clinicaltrials.gov) - Apr 14, 2017
P1, N=45, Recruiting, Sponsor: University of Chicago
N=100 --> 0 | Not yet recruiting --> Withdrawn Trial primary completion date: Mar 2017 --> Sep 2017
- | Avastin (bevacizumab) / Roche
Trial primary completion date, Surgery: Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer (clinicaltrials.gov) - Apr 13, 2017
P2, N=43, Recruiting, Sponsor: University of Southern California
Trial primary completion date: Mar 2017 --> Sep 2017 Trial primary completion date: Jul 2016 --> Aug 2018
- ||||||| Recentin (cediranib) / AstraZeneca
Trial completion, Combination therapy, Metastases: HORIZON III: First Line Metastatic Colorectal Cancer Therapy in Combination With FOLFOX (clinicaltrials.gov) - Apr 13, 2017
P2/3, N=1805, Completed, Sponsor: AstraZeneca
Trial primary completion date: Jul 2016 --> Aug 2018 Active, not recruiting --> Completed
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer. (Pubmed Central) - Apr 13, 2017
Active, not recruiting --> Completed Despite its relatively low accuracy, ITRA might be a useful technique for predicting therapeutic efficacy and selecting for appropriate first-line and second-line anticancer regimens for patients.
- || Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Trial primary completion date, Metastases: MM-398-07-02-03: Study of Nanoliposomal Irinotecan (Nal-IRI)-Containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 12, 2017
P2, N=168, Recruiting, Sponsor: Ipsen
Despite its relatively low accuracy, ITRA might be a useful technique for predicting therapeutic efficacy and selecting for appropriate first-line and second-line anticancer regimens for patients. Trial primary completion date: Mar 2017 --> Oct 2018
- | New P2 trial, Metastases: FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study (clinicaltrials.gov) - Apr 12, 2017
P2, N=38, Not yet recruiting, Sponsor: Samsung Medical Center
- | New P2 trial, Metastases: Induction Chemotherapy for Locally Advanced Esophageal Cancer (clinicaltrials.gov) - Apr 12, 2017
P2, N=40, Not yet recruiting, Sponsor: University of Rochester
- ||| Vectibix (panitumumab) / Amgen
Enrollment closed, Enrollment change, Trial primary completion date: SAPPHIRE: Safety and Efficacy Study of mFOLFOX6 + Panitumumab Combination Therapy and 5-FU/LV + Panitumumab Combination Therapy in Participants With Chemotherapy-na (clinicaltrials.gov) - Apr 11, 2017
P2, N=164, Active, not recruiting, Sponsor: Takeda
Trial primary completion date: Mar 2017 --> Oct 2018 Recruiting --> Active, not recruiting | N=100 --> 164 | Trial primary completion date: Aug 2017 --> Mar 2017
- | thioguanine / Generic mfg., azacitidine / Generic mfg.
Enrollment open: AALL15P1: Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement (clinicaltrials.gov) - Apr 11, 2017
P=N/A, N=116, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=100 --> 164 | Trial primary completion date: Aug 2017 --> Mar 2017 Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> Mar 2017 | Not yet recruiting --> Recruiting
- |||| Vectibix (panitumumab) / Amgen
Biomarker, Trial primary completion date: PARADIGM biomarker: An Exploratory Study of Treatment Sensitivity and Prognostic Factors in a Efficacy and Safety Study of MFOLFOX6 + Bevacizumab Versus MFOLFOX6 + Panitumumab Therapy in Patients with Chemotherapy-na (clinicaltrials.gov) - Apr 10, 2017
P3, N=800, Recruiting, Sponsor: Takeda
Not yet recruiting --> Recruiting | Initiation date: Dec 2016 --> Mar 2017 | Not yet recruiting --> Recruiting Trial primary completion date: Sep 2018 --> Apr 2017
- | Farydak (panobinostat) / Secura Bio
Trial initiation date, Trial primary completion date, Combination therapy: Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov) - Apr 10, 2017
P1, N=36, Recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Sep 2018 --> Apr 2017 Initiation date: Feb 2016 --> May 2016 | Trial primary completion date: Apr 2018 --> Aug 2018
- | 5-fluorouracil / Generic mfg.
Trial primary completion date, Surgery: Radiation Therapy and Fluorouracil With or Without Combination Chemotherapy Followed by Surgery in Treating Patients With Stage II or Stage III Rectal Cancer (clinicaltrials.gov) - Apr 7, 2017
P2, N=248, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Initiation date: Feb 2016 --> May 2016 | Trial primary completion date: Apr 2018 --> Aug 2018 Trial primary completion date: Dec 2017 --> Dec 2018
- | Avastin (bevacizumab) / Roche
Enrollment closed, Trial primary completion date, Combination therapy: FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal Cancer (clinicaltrials.gov) - Apr 7, 2017
P1/2, N=35, Active, not recruiting, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Trial primary completion date: Dec 2017 --> Dec 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Nov 2016
- | Odomzo (sonidegib) / Sun Pharma
Trial primary completion date, Combination therapy, Metastases: LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer (clinicaltrials.gov) - Apr 7, 2017
P1b, N=39, Active, not recruiting, Sponsor: Massachusetts General Hospital
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2017 --> Nov 2016 Trial primary completion date: Sep 2013 --> Apr 2018
- | Trial primary completion date: POWERRANGER: Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma (clinicaltrials.gov) - Apr 7, 2017
P2/3, N=60, Recruiting, Sponsor: Dr. Gordon Buduhan
Trial primary completion date: Sep 2013 --> Apr 2018 Trial primary completion date: Feb 2017 --> Feb 2018
- | leucovorin calcium / Generic mfg.
Phase classification, Trial primary completion date: Methotrexate Infusion Into the Fourth Ventricle in Children With Malignant Fourth Ventricular Brain Tumors: A Pilot Study (clinicaltrials.gov) - Apr 7, 2017
P, N=12, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Trial primary completion date: Feb 2017 --> Feb 2018 Phase classification: P=N/A --> P | Trial primary completion date: Dec 2017 --> Dec 2018
- | Trial initiation date, Combination therapy, IO biomarker: Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma (clinicaltrials.gov) - Apr 7, 2017
P2, N=26, Recruiting, Sponsor: University of Miami
Phase classification: P=N/A --> P | Trial primary completion date: Dec 2017 --> Dec 2018 Initiation date: Apr 2011 --> Apr 2009
- | leucovorin calcium / Generic mfg.
Trial primary completion date: EFFET: Folinic Acid in Children With Autism Spectrum Disorders (clinicaltrials.gov) - Apr 7, 2017
P2, N=40, Recruiting, Sponsor: Central Hospital, Nancy, France
Initiation date: Apr 2011 --> Apr 2009 Trial primary completion date: Jan 2017 --> Jan 2018
- ||| Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Combination therapy, Metastases: Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (clinicaltrials.gov) - Apr 7, 2017
P1, N=60, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Jan 2017 --> Jan 2018 Active, not recruiting --> Recruiting
- | Trial initiation date: Mature B-Cell Lymphoma And Leukemia Study III (clinicaltrials.gov) - Apr 4, 2017
P2/3, N=122, Recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Recruiting Initiation date: Jan 2009 --> Sep 2010
- | Trial completion: Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy (clinicaltrials.gov) - Apr 4, 2017
P1, N=5, Completed, Sponsor: Dana-Farber Cancer Institute
Initiation date: Jan 2009 --> Sep 2010 Active, not recruiting --> Completed
- || Vectibix (panitumumab) / Amgen
Trial primary completion date: Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer (clinicaltrials.gov) - Apr 4, 2017
P2, N=78, Recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Mar 2018
- crenolanib (ARO-002) / AROG
Trial initiation date, Combination therapy: Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies (clinicaltrials.gov) - Apr 4, 2017
P1, N=10, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Trial primary completion date: Mar 2017 --> Mar 2018 Initiation date: Oct 2014 --> Apr 2015
- | New P2 trial: Neoadjuvant Modified FOLFIRINOX and Stereotactic Body Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma (clinicaltrials.gov) - Apr 4, 2017
P2, N=28, Not yet recruiting, Sponsor: Yale University
- | Stivarga (regorafenib) / Bayer
New P2 trial, Monotherapy, Metastases: Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC (clinicaltrials.gov) - Apr 4, 2017
P2, N=15, Not yet recruiting, Sponsor: Fox Chase Cancer Center
- | irinotecan / Generic mfg.
Phase classification, Trial primary completion date, Metastases: Individual Dosage Selection of Irinotecan (CPT-11) Based on UGT1A1 Genotype in Metastatic Colorectal Cancer Patients (clinicaltrials.gov) - Mar 30, 2017
P2/3, N=583, Completed, Sponsor: The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
Initiation date: Oct 2014 --> Apr 2015 Phase classification: P2 --> P2/3 | Trial primary completion date: Dec 2013 --> Nov 2015
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date: Second Look Laparoscopy in Colorectal Cancer (clinicaltrials.gov) - Mar 29, 2017
P2, N=140, Recruiting, Sponsor: National Cancer Institute, Naples
Phase classification: P2 --> P2/3 | Trial primary completion date: Dec 2013 --> Nov 2015 Trial primary completion date: Jun 2016 --> Sep 2017
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment closed, Trial primary completion date, Combination therapy, Metastases: Study of REOLYSIN (clinicaltrials.gov) - Mar 27, 2017
P1, N=32, Active, not recruiting, Sponsor: Oncolytics Biotech
Trial primary completion date: Jun 2016 --> Sep 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Oct 2017
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Enrollment closed, Trial primary completion date, PD(L)-1 Biomarker, Metastases: Study of Pembrolizumab With REOLYSIN (clinicaltrials.gov) - Mar 27, 2017
P1b, N=9, Active, not recruiting, Sponsor: Oncolytics Biotech
Recruiting --> Active, not recruiting | Trial primary completion date: Apr 2017 --> Oct 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Sep 2017
- || ipatasertib (RG7440) / Roche
Trial primary completion date, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Mar 24, 2017
P1, N=123, Active, not recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2017 --> Sep 2017 Trial primary completion date: Feb 2017 --> Oct 2017
- | GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) / Novartis, Yervoy (ipilimumab) / BMS
Trial suspension, Combination therapy, Metastases: FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer (clinicaltrials.gov) - Mar 24, 2017
P2, N=92, Suspended, Sponsor: Sidney Kimmel Comprehensive Cancer Center
Trial primary completion date: Feb 2017 --> Oct 2017 Recruiting --> Suspended
- Avastin (bevacizumab) / Roche, napabucasin (BBI608) / Sumitomo Pharma
Trial completion, Metastases: A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Mar 23, 2017
P1, N=4, Completed, Sponsor: Sumitomo Dainippon Pharma Co., Ltd.
Recruiting --> Suspended Recruiting --> Completed
- | Trial initiation date, Trial primary completion date, Surgery: Surgery Plus Single Agent Chemotherapy Versus Primary Chemotherapy for Gestational Trophoblastic Neoplasms (clinicaltrials.gov) - Mar 22, 2017
P2/3, N=20, Recruiting, Sponsor: Maher elesawi kamel elesawi
Recruiting --> Completed Initiation date: Jun 2015 --> Sep 2015 | Trial primary completion date: Jun 2016 --> Jun 2017
- ||| simmitecan / HaiHe Biopharma, Shanghai Inst. of Materia Medica
Enrollment open, Monotherapy, Metastases: Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Mar 22, 2017
P1, N=158, Recruiting, Sponsor: ShangHai HaiHe Pharmaceutical
Initiation date: Jun 2015 --> Sep 2015 | Trial primary completion date: Jun 2016 --> Jun 2017 Not yet recruiting --> Recruiting
- | Avastin (bevacizumab) / Roche
New P2 trial, Metastases: TRUST: Folfoxiri Plus Bevacizumab Followed by Chemoradiotherapy Plus Bevacizumab in Patients With Resectable Rectal Cancer (clinicaltrials.gov) - Mar 22, 2017
P2, N=49, Active, not recruiting, Sponsor: Azienda Ospedaliero, Universitaria Pisana
- |||| Zaltrap (ziv-aflibercept IV) / Sanofi
Enrollment open: mFOLFOX6 vs. mFOLFOX6 + Aflibercept as Neoadjuvant Treatment in MRI-defined T3-rectal Cancer (clinicaltrials.gov) - Mar 22, 2017
P2, N=209, Recruiting, Sponsor: AIO-Studien-gGmbH
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
New P4 trial: Chemotherapy Combined With CIK Treating Colon Cancer (clinicaltrials.gov) - Mar 21, 2017
P4, N=46, Completed, Sponsor: China Meitan General Hospital